PE20141146A1 - Inhibidores de la enzima activadora de nedd8 - Google Patents

Inhibidores de la enzima activadora de nedd8

Info

Publication number
PE20141146A1
PE20141146A1 PE2014000250A PE2014000250A PE20141146A1 PE 20141146 A1 PE20141146 A1 PE 20141146A1 PE 2014000250 A PE2014000250 A PE 2014000250A PE 2014000250 A PE2014000250 A PE 2014000250A PE 20141146 A1 PE20141146 A1 PE 20141146A1
Authority
PE
Peru
Prior art keywords
enzyme inhibitors
activating enzyme
nedd8 activating
refers
nedd8
Prior art date
Application number
PE2014000250A
Other languages
English (en)
Spanish (es)
Inventor
Ashley Sue Mccarron
Todd B Sells
Matthew Stirling
Stephen G Stroud
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20141146A1 publication Critical patent/PE20141146A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2014000250A 2011-08-24 2012-08-23 Inhibidores de la enzima activadora de nedd8 PE20141146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526830P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
PE20141146A1 true PE20141146A1 (es) 2014-09-21

Family

ID=47747080

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000250A PE20141146A1 (es) 2011-08-24 2012-08-23 Inhibidores de la enzima activadora de nedd8

Country Status (29)

Country Link
US (3) US8809356B2 (enExample)
EP (2) EP2748168A4 (enExample)
JP (1) JP6038150B2 (enExample)
KR (1) KR20140054288A (enExample)
CN (1) CN103889988B (enExample)
AR (1) AR087672A1 (enExample)
AU (1) AU2012298813B2 (enExample)
BR (1) BR112014004239A2 (enExample)
CA (1) CA2846231C (enExample)
CL (1) CL2014000441A1 (enExample)
CO (1) CO6900148A2 (enExample)
CR (1) CR20140128A (enExample)
DO (1) DOP2014000037A (enExample)
EA (1) EA031067B1 (enExample)
EC (1) ECSP14013263A (enExample)
GE (1) GEP201606522B (enExample)
HK (1) HK1199252A1 (enExample)
IL (1) IL231069B (enExample)
MA (1) MA35439B1 (enExample)
MX (1) MX2014002015A (enExample)
MY (1) MY166889A (enExample)
PE (1) PE20141146A1 (enExample)
PH (1) PH12014500419A1 (enExample)
SG (2) SG11201400102WA (enExample)
TN (1) TN2014000080A1 (enExample)
TW (1) TWI577667B (enExample)
UA (1) UA114894C2 (enExample)
UY (1) UY34292A (enExample)
WO (1) WO2013028832A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
UA116534C2 (uk) 2012-02-17 2018-04-10 Мілленніум Фармасьютікалз, Інк. Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту
CN104684559A (zh) 2012-08-03 2015-06-03 米伦纽姆医药公司 针对Uba6的吲哚取代的吡咯并嘧啶基抑制剂
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2015002994A2 (en) * 2013-07-02 2015-01-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
BR112016030787B1 (pt) 2014-07-01 2022-12-20 Takeda Pharmaceutical Company Limited Entidade química, composição farmacêutica e seu uso
WO2017183927A1 (ko) * 2016-04-20 2017-10-26 한국화학연구원 신규한 헤테로고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2018213258A1 (en) * 2017-05-15 2018-11-22 Millennium Pharmaceuticals, Inc. Treatment of merlin-deficient tumors using nae inhibitors
MY202833A (en) 2018-05-08 2024-05-24 Nippon Shinyaku Co Ltd Azabenzimidazole compounds and pharmaceutical
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194446A (en) 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
WO1997005132A1 (en) 1995-07-28 1997-02-13 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
EP1597255A1 (en) 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
HRP20120786T1 (hr) * 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ME02789B (me) * 2006-08-08 2011-06-30 Millennium Pharm Inc Jedinjenja heteroarila korisna kao inhibitori e1 aktivirajućih enzima
EP2430026A1 (en) * 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MY166889A (en) * 2011-08-24 2018-07-24 Millennium Pharm Inc Inhibitors of nedd8-activating enzyme
PL2773360T3 (pl) * 2011-11-03 2018-09-28 Millennium Pharmaceuticals, Inc. Podawanie inhibitora enzymu aktywującego NEDD8 i środka hipometylującego

Also Published As

Publication number Publication date
US20180290983A1 (en) 2018-10-11
US20130150388A1 (en) 2013-06-13
US9850214B2 (en) 2017-12-26
EP3323414A1 (en) 2018-05-23
CN103889988A (zh) 2014-06-25
EP2748168A4 (en) 2015-04-22
AU2012298813A1 (en) 2013-05-02
KR20140054288A (ko) 2014-05-08
TN2014000080A1 (en) 2015-07-01
WO2013028832A2 (en) 2013-02-28
AR087672A1 (es) 2014-04-09
JP6038150B2 (ja) 2016-12-07
GEP201606522B (en) 2016-08-10
CA2846231A1 (en) 2013-02-28
AU2012298813B2 (en) 2016-07-28
EA201400249A1 (ru) 2014-05-30
PH12014500419A1 (en) 2020-06-22
TWI577667B (zh) 2017-04-11
CR20140128A (es) 2014-05-15
BR112014004239A2 (pt) 2017-03-21
MX2014002015A (es) 2014-03-27
CN103889988B (zh) 2018-05-04
SG11201400102WA (en) 2014-03-28
US20150011572A1 (en) 2015-01-08
CO6900148A2 (es) 2014-03-20
US8809356B2 (en) 2014-08-19
MY166889A (en) 2018-07-24
HK1199252A1 (en) 2015-06-26
CA2846231C (en) 2017-06-20
UA114894C2 (uk) 2017-08-28
IL231069B (en) 2018-02-28
IL231069A0 (en) 2014-03-31
ECSP14013263A (es) 2014-04-30
UY34292A (es) 2013-04-05
JP2014524476A (ja) 2014-09-22
MA35439B1 (fr) 2014-09-01
EA031067B1 (ru) 2018-11-30
CL2014000441A1 (es) 2014-09-26
SG10201601023UA (en) 2016-03-30
NZ622220A (en) 2016-04-29
TW201313689A (zh) 2013-04-01
DOP2014000037A (es) 2014-04-15
EP2748168A2 (en) 2014-07-02
WO2013028832A3 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.
BR112015006874A2 (pt) ligantes de rig-i inovadores e métodos para produzir os mesmos
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
NI201400032A (es) Piridopirazinas anticancerígenas via la
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA202190619A1 (ru) Противовирусные соединения
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
BR112014004219A2 (pt) pirano[3,2-d][1,3]tiazol como inibidores de glicosidase
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
BR112015021240A2 (pt) processo para sal de sódio de (2s, 5r)-2-carboxamido-7-oxo-6-sulfo-oxi-1,6-diaza-biciclo[3.2.1]octano
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
EA201490756A1 (ru) Разагилина цитрамид
BR112014024493A2 (pt) método para a produção enzimática de isoprenol usando mevalonato como substrato
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
MX2014004688A (es) Proceso de obtencion de acidos isoxazolil-metoxi-nicotinicos.
EA201391524A1 (ru) Производные гликозида и их применение
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц

Legal Events

Date Code Title Description
FG Grant, registration